Delamanid dosage and administration

Delamanid is a relatively new experimental drug that has shown efficacy against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis. It is approved for the treatment of tuberculosis in EU countries (under the brand name Deltyba) and Japan as part of combination therapy to treat multidrug-resistant tuberculosis.

The recommended dose of delamanid in adults is 100 mg twice daily for 24 weeks; in pediatric patients weighing ≥30 to <50 kg, the recommended dose is 50 mg twice daily for 24 weeks; in adolescents and children ≥50 kg, the recommended dose is 100 mg twice daily for 24 weeks. In a recent clinical trial, 481 MDR-TB patients on a background regimen for MDR-TB were randomized to receive delamanid 100 mg twice daily, delamanid 200 mg twice daily, or placebo. Both delamanid treatment groups (13.1% and 9.9%) demonstrated asymptomatic QT prolongation compared with placebo (3.8%).

The original drug Delamani has been launched in China and is included in the scope of Class B medical insurance. Reimbursement is limited to patients with multi-drug-resistant tuberculosis. Specifications The price of each box of 50mg*60 tablets may be around RMB 6,000. The price of the Russian version of the original drug Dramani, 50mg*48 tablets, sold overseas may be around RMB 1,000-2,000 per box (the price may fluctuate due to the exchange rate). There is currently no generic version of Dramani available on the market. For more drug information and specific prices, please consult Yaode’s medical consultant.